期刊
AIDS AND BEHAVIOR
卷 23, 期 1, 页码 211-221出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10461-018-2241-z
关键词
HIV; Alcohol; Extended-release naltrexone; Randomized clinical trial
资金
- U.S. National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism [5R01AA018923]
- Yale Drug Abuse, Addiction, and HIV Research Scholar [NIDA K12 DA033312]
We sought to test the efficacy of extended-release naltrexone (XR-NTX) on HIV-related and drinking outcomes. From April 2011-February 2015, we conducted a 4-site randomized double-blind placebo controlled clinical trial involving 51 HIV-positive patients with heavy drinking and<95% antiretroviral (ART) adherence. All participants received counseling. The primary outcome was proportion with95% ART adherence. Secondary outcomes included HIV biomarkers, VACS Index score, and past 30-day heavy drinking days. Based on receipt of5 injections, 23 participants were retained at 24weeks. We did not detect an effect of XR-NTX on ART adherence (p=0.38); undetectable HIV viral load (p=0.26); CD4 cell count (p=0.75) or VACS Index score (p=0.70). XR-NTX was associated with fewer heavy drinking days (p=0.03). While XR-NTX decreases heavy drinking days, we did not detect improvements in ART adherence or HIV outcomes. Strategies to improve retention in alcohol treatment and HIV-related outcomes among heavy drinking HIV-positive patients are needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据